Antimicrobial susceptibility of enterococci from Italian patients with infective endocarditis | Zendy

Claudio Farina | Zendy; Giuseppe Russello | Zendy; Annibale Raglio | Zendy; Francesca Vailati | Zendy; Veronica Ravasio | Zendy; Maria Bruna Pasticci | Zendy; Pierangelo Chinello | Zendy; Claudio Scarparo | Zendy; Gruppo SEI | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antimicrobial susceptibility of enterococci from Italian patients with infective endocarditis

Author(s) -

Claudio Farina,

Giuseppe Russello,

Annibale Raglio,

Francesca Vailati,

Veronica Ravasio,

Maria Bruna Pasticci,

Pierangelo Chinello,

Claudio Scarparo,

Gruppo SEI

Publication year - 2010

Publication title -

microbiologia medica

Language(s) - English

Resource type - Journals

eISSN - 2280-6423

pISSN - 1120-0146

DOI - 10.4081/mm.2010.2479

Subject(s) - fosfomycin , linezolid , tigecycline , infective endocarditis , ampicillin , enterococcus faecalis , microbiology and biotechnology , ceftriaxone , moxifloxacin , imipenem , medicine , antimicrobial , endocarditis , antibiotics , vancomycin , biology , staphylococcus aureus , antibiotic resistance , bacteria , genetics

The epidemiological and clinical study “Studio Endocarditi Italiane” (SEI) evaluated 947 cases of infective endocarditis in 2004-2008. Enterococcal aethiology was described in 11% cases.The aim of our study was to evacuate the in vitro activity of twelve antibiotics alone and in association against 20 strains (15 E. faecalis, 5 E. faecium). Results show the in vitro activity of tigecyicline, daptomicine and linezolid. Synergism is appreciated for ceftriaxone-fosfomycin (FICindex50=0.34, FICindex90=0.56) against E. faecalis and for imipenem-fosfomycin against E. faecium.The majority of the tested strains show addition using ampicillin-ceftriaxone (FICindex50=0.85, FICindex90=1.01) and moxifloxacin- tigecycline (FICindex50=0.77, FICindex90=1.96)

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research